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INTRODUCTION 
The human genome comprises approximately 23,000 protein-
coding genes.1  For over thirty years, the United States Patent and 
Trademark Office (PTO) has issued patents on isolated 
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 1. Int’l Human Genome Sequencing Consortium, Finishing the Euchromatic 
Sequence of the Human Genome, 431 NATURE 931, 942 (2004). 
444 AMERICAN UNIVERSITY LAW REVIEW [Vol. 61:443 
deoxyribonucleic acid (DNA) molecules encoding sequences 
identical to human genes as found in nature.2  As a result, 
approximately 20% of all human genes are patented, some as many 
as twenty times.3  A number of patents claim isolated DNA molecules 
encoding mutations that increase a person’s risk of developing 
disease, making them useful tools for genetic testing.4  Proponents of 
gene patenting assert that such patents stimulate investment and 
research by rewarding scientists with exclusive rights in their 
invention.5  Opponents, on the other hand, argue that gene patents 
impede access to patient testing, decrease the quality of genetic 
testing, and create barriers to research.6 
Though the statutory definition of patentable material7 has been 
                                                          
 2. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office (Myriad), 
653 F.3d 1329, 1355, 99 U.S.P.Q.2d (BNA) 1398, 1418 (Fed. Cir. 2011). 
 3. Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the Human 
Genome, 310 SCI. 239, 239 (2005).  The subject matter of gene patenting is not the 
genes themselves, but isolated DNA molecules comprising sequences identical to the 
sequences of the human gene as found in nature, a composition of matter.  See, e.g., 
Myriad, 653 F.3d at 1351, 99 U.S.P.Q.2d (BNA) at 1415 (providing an example of a 
claimed isolated DNA molecule and describing the relationship between isolated 
DNA sequences and naturally occurring DNA or genes).  As used in this Note, “gene 
patents” or “gene patenting” refer to the patenting of the isolated DNA molecule, 
not to the gene sequence itself. 
 4. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. 
Supp. 2d 181, 195, 94 U.S.P.Q.2d (BNA) 1683, 1693 (S.D.N.Y. 2010) (discussing the 
connection between genetic mutations and the propensity for particular diseases), 
aff’d in part, rev’d in part, 653 F.3d 1329, 99 U.S.P.Q.2d (BNA) 1398 (Fed. Cir. 2011).  
 5. See Myriad Defendants’ Memorandum of Law (1) in Support of Their Motion 
for Summary Judgment & (2) in Opposition to Plaintiffs’ Motion for Summary 
Judgment at 46, Ass’n for Molecular Pathology, 702 F. Supp. 2d 181, 94 U.S.P.Q.2d 
(BNA) 1683 (No. 09 Civ. 4515), 2009 WL 5785008 at *53 [hereinafter Myriad’s 
Memo] (indicating that at least 8600 research papers have been directed toward 
Myriad’s claimed gene sequences since their disclosure); SEC’Y’S ADVISORY COMM. ON 
GENETICS, HEALTH, & SOC’Y, U.S. DEP’T OF HEALTH & HUMAN SERVS., GENE PATENTS 
AND LICENSING PRACTICES AND THEIR IMPACT ON PATIENT ACCESS TO GENETIC TESTS 28–
29 (2010) [hereinafter SACGHS REPORT], available at http://oba.od.nih.gov/oba/ 
SACGHS/reports/SACGHS_patents_report_2010.pdf (summarizing legal and 
economic scholarship and public comments supporting the view that patents 
stimulate investment in genetic testing); Lisa A. Haile, IP Position Critical to Biotech 
Investment, WALL STREET BIOBEAT (Apr. 1, 2010), http://www.genengnews.com/gen-
articles/ip-position-critical-to-biotech-investment/3235/ (noting that the strength of 
a company’s intellectual property strategy and position is one of the top three 
questions posed by investors). 
 6. See, e.g., SACGHS REPORT, supra note 5, at 39–45 (explaining that limited 
access arises in the context of a sole testing provider because lack of competition 
inflates prices above what insurance companies will cover); Steve Benowitz, French 
Challenge to BRCA1 Patent Underlies European Discontent, 94 J. NAT’L CANCER INST. 80–81 
(2002) (finding that Myriad’s testing procedure failed to detect ten to twenty percent 
of mutations); John P. Walsh et al., View from the Bench:  Patents and Materials Transfers, 
309 SCI. 2002, 2002 (2005) (determining that out of 381 academic scientists, none 
stopped their research due to the existence of patents). 
 7. 35 U.S.C. § 101 (2006) (providing that a patent is available for new and 
2011] MYRIAD:  ISOLATED DNA MOLECULES ARE PATENTABLE 445 
broadly construed, the United States Supreme Court has recognized 
three judicially-created exceptions to patentability:  laws of nature, 
physical phenomena, and abstract ideas.8  Recently, the United States 
District Court for the Southern District of New York determined that 
claims to isolated DNA molecules cover patent-ineligible products of 
nature, asserting that as the physical embodiment of biological 
information, DNA represents the physical embodiment of laws of 
nature.9  In Ass’n for Molecular Pathology v. United States Patent & 
Trademark Office (Myriad),10 the United States Court of Appeals for the 
Federal Circuit reversed the district court’s decision, holding that 
claims to such isolated DNA are patentable subject matter.11  Through 
scientific analysis, the court reasoned that the chemical and structural 
differences between isolated DNA molecules and DNA as found in 
nature were “distinctive,” rendering isolated DNA molecules patent-
eligible.12 
This Note examines the Myriad decision, analyzing the science 
behind isolated DNA in light of historical Supreme Court 
jurisprudence regarding the patentability of inventions derived from 
nature.  Part I examines the science of DNA and sets forth the facts 
and procedural history of the case.  Part II argues that Supreme 
Court decisions regarding the patentability of inventions derived 
from nature require an assessment of the differences between the 
claimed subject matter and that found in nature.  Part II further 
argues that the Federal Circuit correctly found that isolated DNA 
molecules are patent-eligible under this analysis, and that the Myriad 
decision supports stability within the patent system.  This Note 
concludes that by following the analytical framework set forth in 
Myriad, which emphasizes the differences between an invention and a 
                                                          
useful inventory and discoveries, or new and useful improvements on existing 
patents). 
 8. See Diamond v. Chakrabarty, 447 U.S. 303, 309, 206 U.S.P.Q. (BNA) 193, 197 
(1980) (citing Parker v. Flook, 437 U.S. 584, 198 U.S.P.Q. (BNA) 193 (1978); 
Gottschalk v. Benson, 409 U.S. 63, 67, 175 U.S.P.Q. (BNA) 673, 675 (1972); Funk 
Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130, 76 U.S.P.Q. (BNA) 280, 281 
(1948); O’Reilly v. Morse, 56 U.S. (15 How.) 62, 112–21 (1854); Le Roy v. Tatham, 
55 U.S. (14 How.) 156, 175 (1853)) (providing examples of such exceptions of a new 
mineral found in the earth, a new plant found in the wild, Einstein’s law that E=mc2, 
and Newton’s law of gravity). 
 9. See Ass’n for Molecular Pathology, 702 F. Supp. 2d at 228, 94 U.S.P.Q.2d (BNA) 
at 1719 (holding invalid claims to not only isolated DNA molecules comprising 
sequences identical to those found in nature but also cDNA, which is synthesized 
from a natural template). 
 10. 653 F.3d 1329, 99 U.S.P.Q.2d (BNA) 1398 (Fed. Cir. 2011). 
 11. Id. at 1352–54, 99 U.S.P.Q.2d (BNA) at 1416–17. 
 12. Id. at 1350–51, 99 U.S.P.Q.2d (BNA) at 1415. 
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product of nature, courts will promote scientific progress by avoiding 
fundamental changes to more than a century of precedent and PTO 
practice in the field of biotechnology. 
I. BACKGROUND 
A. The Science of DNA 
DNA exists in nature as linear sequences of nucleotides (chemical 
units that include one of four bases:  adenine, thymine, guanine, and 
cytosine) that are packaged into chromosomes.13  Each chromosome 
contains hundreds of genes, occurring one after the other as discrete 
lengths of sequence within the linear DNA.14  The order of the 
nucleotide sequences within a gene determines the function of the 
protein produced by that gene, and the characteristics of individual 
proteins collectively contribute to the genetic traits of a person.15  
During transcription, DNA is copied repeatedly into a similar form 
known as messenger RNA (mRNA).16  Subsequently, during 
translation, protein is synthesized according to the mRNA 
templates.17  The resulting proteins then interact to perform a host of 
functions within the cell.  A simple analogy illustrates the concept:  a 
person reads instructions (DNA) for how to put a table together, and 
that person’s brain processes the information (transcription) into a 
signal (mRNA); that signal (mRNA) instructs the body to carry out 
the processed instructions from the brain to put the table’s 
components (proteins) together (translation). 
Importantly, alterations of the nucleotide sequences, called 
mutations, can occur.18  Genetic mutations can increase a person’s 
risk of developing a variety of serious diseases, including cancer.19  
                                                          
 13. HARVEY LODISH ET AL., MOLECULAR CELL BIOLOGY 8, 101–03 (4th ed. 2001). 
 14. Id. at 4, 8.   
 15. See id. at 5, 100–01 (discussing the central dogma of molecular biology—the 
sequence of DNA directs the synthesis of RNA, which then directs assembly of 
proteins). 
 16. See id. at 111–16 (providing an overview of transcription). 
 17. See id. at 116–19, 127 (providing an overview of translation).  DNA includes 
both coding (“exons”) and non-coding (“introns”) lengths of nucleotide sequence.  
Id. at 116.  During transcription, introns are excised (“spliced”) from mRNA, leaving 
only the exons.  Id.  cDNA, synthesized from an mRNA template in the laboratory, 
contains only the sequence of the exons, an important distinction noted in all three 
opinions produced by the Myriad court.  Id. at 219.   
 18. Id. at 254.   
 19. Id. at 258–59, 1061; see also Marisa Noelle Pins, Note, Impeding Access to Quality 
Patient Care and Patient Rights:  How Myriad Genetics’ Gene Patents Are Unknowingly 
Killing Cancer Patients and How to Calm the Ripple Effect, 17 J. INTELL. PROP. L. 377, 384 
(2010) (noting that, though some inherited mutations are innocuous, others may 
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Likewise, specific mutations of BRCA1/2, 20 the gene at issue in 
Myriad, increase the risk of breast and ovarian cancer.21  Because an 
increased risk for breast or ovarian cancer has implications for an 
individual’s choice of lifestyle and preventative care, the scientific 
and healthcare communities are intensifying research into genetic 
testing to facilitate early identification of BRCA1/2 mutations in 
patients.22  Current testing relies on the isolated DNA molecules 
encoding BRCA1/2 gene sequences claimed by Myriad’s patents.23 
B. Facts and Procedural History 
Myriad Genetics (“Myriad”) holds several patents,24 claiming, inter 
alia, isolated DNA molecules encoding the human BRCA1/2 genes.25  
A representative composition claim reads, “[a]n isolated DNA coding 
for a BRCA1 polypeptide, said polypeptide having the [following] 
amino acid sequence.”26  Certain mutations of the BRCA1/2 genes 
                                                          
increase a person’s risk for a variety of diseases). 
 20. BRCA1 and BRCA2 stand for “breast cancer 1, early onset,” and “breast 
cancer 2, early onset,” respectively.  See, e.g., Homo Sapiens Breast Cancer 2, Early Onset 
(BRCA2), mRNA, NIH NCBI GenBank, http://www.ncbi.nlm.nih.gov/nuccore/ 
NM_000059.3 (last visited Nov. 14, 2011). 
 21. The average woman in the United States, without such a mutation, has about 
a 12% chance of developing breast cancer in her lifetime, but carriage of an 
abnormal BRCA1 or BRCA2 gene augments this to about an 80% chance.  Genetics, 
BREASTCANCER.ORG, http://www.breastcancer.org/risk/factors/genetics.jsp (last 
modified Feb. 15, 2011).  Such mutations also increase a woman’s risk for developing 
ovarian, colon, pancreatic, and thyroid cancers.  Id. 
 22. See, e.g., Study Groups, CIMBA (THE CONSORTIUM OF INVESTIGATORS OF 
MODIFIERS OF BRCA1/2), http://www.srl.cam.ac.uk/consortia/cimba/groups/ 
groups.html (last visited Nov. 2, 2011) (listing fifty-one members worldwide of a 
scientific consortium for researching BRCA1/2). 
 23. See SACGHS REPORT, supra note 5, at 23 (noting that Myriad’s patent 
holdings have made it the sole provider of BRCA testing in the United States). 
 24. Complaint ¶ 31, Ass’n for Molecular Pathology v. U.S. Patent & Trademark 
Office, 702 F. Supp. 2d 181, 94 U.S.P.Q.2d (BNA) 1683 (S.D.N.Y. 2010) (No. 09 Civ. 
4515), 2009 WL 1343027 at *14 [hereinafter AMP Complaint].  The challenged 
patents include U.S. Patent No. 5,747,282 (filed June 7, 1995), U.S. Patent No. 
5,837,492 (filed Apr. 29, 1996), U.S. Patent No. 5,693,473 (filed June 7, 1995), U.S. 
Patent No. 5,709,999 (filed June 7, 1995), U.S. Patent No. 5,710,001 (filed June 7, 
1995), U.S. Patent No. 5,753,441 (filed Jan. 5, 1996), and U.S. Patent No. 6,033,857 
(filed Mar. 20, 1998).  Id. ¶ 32(a)–(d). 
 25. The composition claims are directed toward isolated DNA sequences having 
identity to both the sequence as it exists in the human body as well as to cDNA 
sequences.  See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office 
(Myriad), 653 F.3d 1329, 1349–50, 99 U.S.P.Q.2d (BNA) 1398, 1414 (Fed. Cir. 2011) 
(including cDNA molecules in holding that isolated DNA molecules are patentable); 
see also supra text accompanying note 17 (describing the difference between native 
DNA and cDNA).  Collectively, the patents also claim methods of analyzing or 
comparing a patient’s BRCA1/2 sequence with normal or mutated sequences and a 
method claim directed to a method of screening potential cancer therapeutics.  
Myriad, 653 F.3d at 1334, 99 U.S.P.Q.2d (BNA) at 1402. 
 26. U.S. Patent No. 5,747,282 col.153 ll.57–58 (filed June 7, 1995). 
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result in an increased risk of the development of breast and ovarian 
cancer.27  By securing its intellectual property through these patents, 
Myriad has established itself as the sole provider of commercial 
genetic testing related to breast and ovarian cancer linked to the 
BRCA1/2 genes.28 
On May 12, 2009, the Association for Molecular Pathology (AMP) 
and nineteen other plaintiffs, including healthcare associations, 
individual doctors, researchers, and patients, filed a lawsuit against 
the PTO, Myriad, and ten other individual defendants in their 
capacity as Directors of the University of Utah Research Foundation 
challenging the validity of Myriad’s gene patents.29  AMP alleged that 
the patent claims were invalid under 35 U.S.C. § 101 because “human 
genes are products of nature,” and, as such, they do not constitute 
patentable subject matter.30 
On March 29, 2010, the Southern District of New York granted the 
plaintiffs’ motion for summary judgment, holding the patents related 
to BRCA1/2 invalid.31  The court asserted that, “DNA represents the 
physical embodiment of biological information, distinct in its 
essential characteristics from any other chemical found in nature.”32  
By conveying information defining the construction of the human 
body, DNA serves as a “physical embodiment of laws of nature.”33  
Therefore, the court concluded that the isolated DNA molecules 
containing sequences found in nature were unpatentable subject 
matter under 35 U.S.C. § 101.34  Myriad filed a Notice of Appeal to 
                                                          
 27. Myriad, 653 F.3d at 1338–39, 99 U.S.P.Q.2d (BNA) at 1405.   
 28. AMP Complaint, supra note 24, ¶ 48.  Though Myriad regularly enforces its 
patents against entities providing commercial diagnostic testing, it does not enforce 
its patents against research activities of academic institutions.  See, e.g., Ass’n for 
Molecular Pathology v. U.S. Patent & Trademark Office, 669 F. Supp. 2d 365, 379 
(S.D.N.Y. 2009) (referencing a letter to a National Cancer Institute investigator 
assuring her that Myriad would not interfere with her research activities despite the 
fact that it had attempted to block the commercial use of BRCA1/2 by other labs), 
aff’d in part, rev’d in part, 653 F.3d 1329, 99 U.S.P.Q.2d 1398 (Fed. Cir. 2011). 
 29. AMP Complaint, supra note 24, ¶¶ 27–29, 32. 
 30. Id. ¶ 102.  The plaintiffs also alleged invalidity under the United States 
Constitution, specifically under Article 1, Section 8, clause 8, the First Amendment, 
and the Fourteenth Amendment.  Id. ¶¶ 102–03.  The district court ultimately 
dismissed these claims under the doctrine of constitutional avoidance.  Ass’n for 
Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 181, 238, 94 
U.S.P.Q.2d (BNA) 1683, 1726 (S.D.N.Y. 2010), aff’d in part, rev’d in part, 653 F.3d 
1329, 99 U.S.P.Q.2d 1398 (Fed. Cir. 2011).  
 31. Ass’n for Molecular Pathology, 702 F. Supp. 2d at 232, 238, 94 U.S.P.Q.2d (BNA) 
at 1722, 1726. 
 32. Id. at 185, 94 U.S.P.Q.2d (BNA) at 1686. 
 33. Id. at 228, 94 U.S.P.Q.2d (BNA) at 1719. 
 34. Id. at 232, 94 U.S.P.Q.2d (BNA) at 1722.  The courts have excluded from 
patentable subject matter laws of nature, physical phenomena, and abstract ideas.  See 
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the Federal Circuit on June 16, 2010,35 which heard oral arguments 
on April 4, 2011.36 
II. ANALYSIS 
A. Section 101 Analyses Should Focus on Differences from Naturally 
Occurring Compositions Rather Than Similarities 
35 U.S.C. § 101 states that “[w]hoever invents or discovers any new 
and useful . . . composition of matter . . . may obtain a patent 
therefor.”37  This section has been broadly construed, including as 
statutory subject matter “anything under the sun that is made by 
man.”38  In the same breath, the Supreme Court has recognized three 
judicially-created exceptions to patentability:  laws of nature, physical 
phenomena, and abstract ideas.39 
As previous cases illustrate, not all inventions derived from nature 
                                                          
supra note 8 and accompanying text.  Here, the court reasoned that the “essential 
characteristic” of DNA is its underlying nucleotide sequence.  Ass’n for Molecular 
Pathology, 702 F. Supp. 2d at 231–32, 94 U.S.P.Q.2d (BNA) at 1721.  Because the 
claimed invention does not differ from native DNA with regard to the underlying 
sequence, the court held that the claimed DNA was not patentable subject matter, as 
it was essentially an embodiment of a law of nature.  Id. at 232, 94 U.S.P.Q.2d (BNA) 
at 1722.  The court further concluded that the claimed comparisons of DNA involved 
in the diagnostic methods were simply abstract mental processes, also rendering 
them unpatentable under 35 U.S.C. § 101.  Id. at 232–37, 94 U.S.P.Q.2d (BNA) at 
1722–25. 
 35. Myriad Defendants’ Notice of Appeal, Ass’n for Molecular Pathology, 702 F. 
Supp. 2d 181, 94 U.S.P.Q.2d 1683 (No. 09 Civ. 4515). 
 36. Oral Argument, Ass’n for Molecular Pathology v. U.S. Patent & Trademark 
Office (Myriad), 653 F.3d 1329, 99 U.S.P.Q.2d (BNA) 1398 (Fed. Cir. 2011) (No. 
2010-1406), available at http://www.cafc.uscourts.gov/oral-argument-recordings/ 
2010-1406/all (click “2010-1406.mp3” link); see Ryan B. Chirnomas, AMP v. 
U.S.P.T.O.:  Oral Argument at the Federal Circuit, PATENT LAW PRACTICE CTR. (Apr. 5, 
2011, 12:21 PM), http://patentlawcenter.pli.edu/2011/04/05/ampvuspto/ 
(summarizing oral arguments in the Myriad case). 
 37. 35 U.S.C. § 101 (2006) (codification of the amended Patent Act of 1952). 
 38. Diamond v. Chakrabarty, 447 U.S. 303, 309, 206 U.S.P.Q. (BNA) 193, 197 
(1980) (quoting S. REP. NO. 82-1979, at 5 (1952); H.R. REP. NO. 82-1923, at 6 (1952)) 
(internal quotation marks omitted); see also Bilski v. Kappos, 130 S. Ct. 3218, 3225, 95 
U.S.P.Q.2d (BNA) 1001, 1005 (2010) (noting that the Supreme Court construed § 
101 broadly because “Congress plainly contemplated that the patent laws would be 
given wide scope” (quoting Chakrabarty, 447 U.S. at 308, 206 U.S.P.Q. (BNA) at 197) 
(internal quotation marks omitted)). 
 39. See Chakrabarty, 447 U.S. at 309, 206 U.S.P.Q. (BNA) at 197 (citing Parker v. 
Flook, 437 U.S. 584, 198 U.S.P.Q. (BNA) 193, 195 (1978) (rejecting a patent for a 
mathematical formula); Gottschalk v. Benson, 409 U.S. 63, 67, 175 U.S.P.Q. (BNA) 
673, 675 (1972) (rejecting a patent for a mathematical formula); Funk Bros. Seed 
Co. v. Kalo Inoculant Co., 333 U.S. 127, 130, 76 U.S.P.Q. (BNA) 280, 281 (1948) 
(“For patents cannot issue for the discovery of the phenomena of nature.”); O’Reilly 
v. Morse, 56 U.S. (15 How.) 62, 112–21 (1854) (rejecting a claim to all use of 
electromagnetism as a motive power); Le Roy v. Tatham, 55 U.S. (14 How.) 156, 175 
(1853) (proposing that “a principle is not patentable”)). 
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are necessarily excluded from patentability.40  Therefore, the Federal 
Circuit looked to the Supreme Court’s decisions in Funk Bros. Seed Co. 
v. Kalo Inoculant Co.41 and Diamond v. Chakrabarty42 to frame its 
decision that isolated DNA molecules are patentable subject matter.43  
In Funk Bros., the patent-in-suit claimed a mixture of several nitrogen-
fixing bacteria strains that did not mutually inhibit one another, 
making the mixture capable of inoculating a broader range of 
leguminous plants than single-species cultures.44  The Court held that 
the mixture was not patentable because no individual species within 
the mixture acquired a novel use or underwent an enlargement of 
utility.45  In Chakrabarty, the Court determined that a bacterium 
genetically engineered to include four naturally occurring DNA 
plasmids was patentable subject matter.46  It reasoned that the claim 
was not for a natural phenomenon, but for a composition of matter 
“having a distinctive name, character [and] use” resulting from 
human ingenuity.47  Distinguishing Funk Bros., the Chakrabarty Court 
                                                          
 40. See, e.g., Chakrabarty, 447 U.S. at 305, 310, 206 U.S.P.Q. (BNA) at 195, 197 
(validating a patent for a genetically engineered microorganism); In re Kubin, 561 
F.3d 1351, 1352, 90 U.S.P.Q.2d (BNA) 1417, 1418 (Fed. Cir. 2009) (invalidating 
isolated DNA molecules encoding Natural Killer Cell Activation Inducing Ligand 
only for obviousness and lack of a written description); Amgen, Inc. v. Chugai 
Pharm. Co., 927 F.2d 1200, 1204, 1219, 18 U.S.P.Q.2d (BNA) 1016, 1019, 1031 (Fed. 
Cir. 1991) (validating and enforcing a claim of isolated DNA molecules encoding 
human erythropoietin); Merck & Co. v. Olin Mathieson Chem. Corp., 253 F.2d 156, 
157, 164, 116 U.S.P.Q. (BNA) 484, 485, 490 (4th Cir. 1958) (validating a patent on a 
form of vitamin B12); Kuehmsted v. Farbenfabriken of Elberfeld Co., 179 F. 701, 705 
(7th Cir. 1910) (enforcing a patent claiming aspirin); Union Carbide Co. v. Am. 
Carbide Co., 181 F. 104, 105, 110 (2d Cir. 1910) (enforcing a patent for a form of 
crystalline calcium carbide); Parke-Davis & Co. v. H. K. Mulford Co., 189 F. 95, 97, 
103 (C.C.S.D.N.Y. 1911) (enforcing a patent claiming extracted adrenalin), aff’d in 
part, rev’d in part, 196 F. 496 (2d Cir. 1912);  In re Bergstrom, 427 F.2d 1394, 1400, 
166 U.S.P.Q. (BNA) 256, 261 (C.C.P.A. 1970) (validating a patent for two types of 
purified prostaglandins); In re Williams, 171 F.2d 319, 319–20, 80 U.S.P.Q. (BNA) 
150, 150–52 (C.C.P.A. 1948) (upholding a claim of a laevo rotary form of a lactone 
compound). 
 41. 333 U.S. 127, 76 U.S.P.Q. (BNA) 280 (1948). 
 42. 447 U.S. 303, 206 U.S.P.Q. (BNA) 193 (1980). 
 43. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office (Myriad), 
653 F.3d 1329, 1350, 99 U.S.P.Q.2d (BNA) 1398, 1414 (Fed. Cir. 2011). 
 44. Funk Bros., 333 U.S. at 129–30, 76 U.S.P.Q. (BNA) at 281.   
 45. Id. at 131, 76 U.S.P.Q. (BNA) at 281–82.  Though invalidated by the district 
court for obviousness, a § 103 determination, the Court cast its decision in terms of § 
101, stating that the bacteria’s non-inhibition qualities were the work of nature, “like 
the heat of the sun, electricity, or the qualities of metals.”  Id. at 130, 76 U.S.P.Q. 
(BNA) at 281. 
 46. Chakrabarty, 447 U.S. at 305 n.1, 310, 206 U.S.P.Q. (BNA) at 195 n.1, 197. 
 47. Id. at 309–10, 206 U.S.P.Q. (BNA) at 197 (quoting Hartranft v. Wiegmann, 
121 U.S. 609, 615 (1887)) (internal quotation marks omitted); see also S. REP. NO. 71-
315, at 6 (1930) (distinguishing a plant discovery resulting from cultivation from the 
mining of a natural mineral); H.R. REP. NO. 71-1129, at 7 (1930) (same). 
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noted that, due to Chakrabarty’s efforts, the bacterium acquired 
characteristics markedly different from any bacterium found in 
nature.48 
Thus, Supreme Court jurisprudence directs that § 101 analyses 
turn on a change in a claimed composition’s identity compared with 
what exists in nature.49  Rather than examining whether isolated DNA 
molecules are markedly different from native DNA molecules, 
however, the Southern District of New York focused on the similarity 
between the information content of isolated and native DNA 
molecules’ nucleotide sequences.50  By focusing on DNA’s genetic 
function of transmitting information, the district court characterized 
DNA as an unpatentable law of nature, effectively creating a 
categorical rule excluding all isolated gene sequences from patent 
eligibility.51  The district court’s failure to take into account 
differences in chemical structure between the molecules constituted 
an erroneous comparative analysis.52  Because isolated DNA 
molecules have markedly different chemical structures compared to 
native DNA molecules, the Federal Circuit rejected the district court’s 
“unwarranted” categorical exclusion of isolated DNA molecules from 
patentability.53 
The Federal Circuit’s majority opinion further emphasized that 
patentability depends on the distinctive chemical and structural 
nature of isolated DNA molecules rather than their physiological use 
                                                          
 48. Chakrabarty, 447 U.S. at 310, 206 U.S.P.Q. (BNA) at 197. 
 49. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office (Myriad), 
653 F.3d 1329, 1351, 99 U.S.P.Q.2d (BNA) 1398, 1415 (Fed. Cir. 2011). 
 50. Id. at 1353, 99 U.S.P.Q.2d (BNA) at 1416.  DNA sequences per se are not 
patentable subject matter.  See Amgen, Inc. v. Chugai Pharm. Co., No. 87-2617-Y, 
1989 WL 169006, at *32, 13 U.S.P.Q.2d (BNA) 1737, 1759 (D. Mass. Dec. 11, 1989) 
(stating that a sequence would be a nonpatentable natural phenomenon), aff’d in 
part, vacated in part, 927 F.2d 1200, 1219, 18 U.S.P.Q.2d (BNA) 1016, 1031 (Fed. Cir. 
1991). 
 51. Myriad, 653 F.3d at 1353, 99 U.S.P.Q.2d (BNA) at 1416.  In recent years, the 
Supreme Court has tended to disparage the creation of categorical rules in patent 
jurisprudence.  See Bilski v. Kappos, 130 S. Ct. 3218, 3227, 95 U.S.P.Q.2d (BNA) 1001, 
1007 (2010) (rejecting exclusive application of the machine-or-transformation test 
for § 101 determinations, which would categorically exclude business methods from 
patent eligibility); KSR Int’l Co. v. Teleflex, Inc., 550 U.S. 398, 419, 82 U.S.P.Q.2d 
(BNA) 1385, 1396 (2007) (same regarding use of the teaching, suggestion, or 
motivation test for § 103 determinations); Chakrabarty, 447 U.S. at 314–17, 206 
U.S.P.Q. (BNA) at 199–200 (rejecting a categorical rule excluding living organisms 
from patent eligibility, and instead promoting legislative and executive limitations in 
this field); see also Diamond v. Diehr, 450 U.S. 175, 182, 209 U.S.P.Q. (BNA) 1, 6 
(1981) (cautioning courts to avoid reading into the patent laws limitations and 
conditions not expressed by the legislature). 
 52. Myriad, 653 F.3d at 1353, 1355, 99 U.S.P.Q.2d (BNA) at 1416, 1418. 
 53. Id. at 1353, 99 U.S.P.Q.2d (BNA) at 1417. 
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or benefit.54  Accordingly, the court observed that patent disclosures 
are better described by the chemical structure of genes, even though 
biologists’ primary consideration may be the function of DNA 
molecules.55  Though such assertions may appear to preclude a 
utilitarian analysis, precedent requires consideration of whether the 
intervention of man imparts a new utility that renders the 
composition markedly different from nature.56  In fact, differences in 
utility may provide guidance as to whether the chemical structure of 
an isolated composition differs from its structure in nature.57 
B. Differences Between the Chemical Structures of Isolated and Native DNA 
Molecules Render Isolated DNA Molecules Patentable 
As the Federal Circuit concluded, Myriad’s claimed isolated DNA 
molecules indisputably exist in a chemical form distinctive from 
native DNA molecules.58  In their native forms, genes exist as discrete 
lengths embedded within a contiguous DNA molecule.59  Forty-six 
such contiguous DNA molecules, in combination with several 
structural proteins, are packaged into larger complexes called 
chromosomes.60  Isolated DNA molecules, on the other hand, are 
freestanding portions of a native DNA molecule, chemically cleaved 
from the chromosomal structure, representing a fraction of the DNA 
                                                          
 54. Id., 99 U.S.P.Q.2d (BNA) at 1416.   
 55. See id. at 1353–54, 99 U.S.P.Q.2d (BNA) at 1416–17 (noting that the utility of 
chemical substances, and therefore isolated DNA sequences, may be relevant to 
obviousness and patentable subject matter determinations). 
 56. See id. at 1364–65, 99 U.S.P.Q.2d (BNA) at 1425 (Moore, J., concurring in 
part) (concluding that not only the different chemical structure but also the 
different and beneficial utility resulting from that chemical structure makes isolated 
DNA molecules patentable). 
 57. See, e.g., Merck & Co. v. Olin Mathieson Chem. Corp., 253 F.2d 156, 164, 116 
U.S.P.Q. (BNA) 484, 490 (4th Cir. 1958) (upholding patentability of a fermentation-
produced vitamin B12 compound having higher activity levels than vitamin B12 
produced in the liver because the development resulted in increased therapeutic and 
commercial worth); Union Carbide Co. v. Am. Carbide Co., 181 F. 104, 107 (2d Cir. 
1910) (holding crystalline product patentable where physical properties were better 
suited for commercial use in gas generators than those of the natural amorphous 
product); Kuehmsted v. Farbenfabriken of Elberfeld Co., 179 F. 701, 705 (7th Cir. 
1910) (upholding a patent for a form of aspirin purified by a process resulting in an 
increased therapeutic effect compared to aspirin purified by previous methods); 
Parke-Davis & Co. v. H. K. Mulford Co., 189 F. 95, 103 (C.C.S.D.N.Y. 1911) (holding 
adrenaline patentable because purification from the adrenal gland transformed it 
into a new substance commercially and therapeutically), aff’d in part, rev’d in part, 196 
F. 496 (2d Cir. 1912). 
 58. Myriad, 653 F.3d at 1353, 99 U.S.P.Q.2d (BNA) at 1417. 
 59. Id., U.S.P.Q.2d (BNA) at 1416; LODISH ET AL., supra note 13, at 4, 8. 
 60. Myriad, 653 F.3d at 1352, 99 U.S.P.Q.2d (BNA) at 1415; LODISH ET AL., supra 
note 13, at 8. 
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molecule as found in nature.61  For example, BRCA1, despite residing 
on a chromosome containing approximately eighty million 
nucleotides, comprises only about eighty thousand nucleotides.62  
Such isolation requires chemical modification through severing of 
the covalent bonds in the backbone of the larger contiguous DNA 
molecule, and structural modification by disassociating the DNA 
molecule from chromosomal structural proteins.63  Thus, the human 
intervention required to isolate a specific DNA molecule imparts a 
chemical identity on such isolated DNA molecules distinct from 
native DNA molecules.64  Accordingly, the BRCA1/2 molecules 
claimed by Myriad are not the same as BRCA1/2 molecules as they 
exist in the body.65 
In addition, the markedly different chemical structure of isolated 
DNA compared to that of native DNA is critically important to the 
isolated DNA molecule’s utility.66  Isolation allows scientists to focus 
on the sequence of interest by removing potentially confounding 
sequences naturally present in the larger chromosomal DNA.67  
Isolation also renders DNA molecules useful as physical probes and 
primers to identify genetic mutations.68  Native DNA molecules simply 
                                                          
 61. Myriad, 653 F.3d at 1352, 99 U.S.P.Q.2d (BNA) at 1415. 
 62. Id., 99 U.S.P.Q.2d (BNA) at 1415 (further explaining that BRCA1 cDNA, with 
the exclusion of introns, consists of approximately 5500 nucleotides).  Some of 
Myriad’s claims cover isolated DNAs having as few as fifteen nucleotides of a BRCA 
sequence.  U.S. Patent No. 5,747,282 col.153, ll.66–67, col.154, ll.56–57 (filed June 7, 
1995) (claims five and six). 
 63. Myriad, 653 F.3d at 1352, 99 U.S.P.Q.2d (BNA) at 1415.  A covalent bond 
defines the boundary between one molecule and another, in this case separating one 
chemical species from another.  Id. at 1353, 99 U.S.P.Q.2d (BNA) at 1416.  Such 
disassociation can be likened to the purification of prostaglandins in In re Bergstrom.  
427 F.2d 1394, 1401 & n.10, 166 U.S.P.Q. (BNA) 256, 261–62 & n.10 (C.C.P.A. 1970) 
(noting that purified prostaglandins were not naturally occurring because they were 
not found in nature in their pure form, separate from all heterogeneous or 
extraneous matter). 
 64. Myriad, 653 F.3d at 1353, 99 U.S.P.Q.2d (BNA) at 1416.  Isolation of a DNA 
molecule changes its size, inter alia, thereby altering its chemical identity.  Similarly, 
in Diamond v. Chakrabarty, the addition of DNA to a microorganism resulted in a 
change in the microorganism’s chemical identity.  447 U.S. 303, 309–10, 206 
U.S.P.Q. (BNA) 193, 197 (1980). 
 65. Myriad, 653 F.3d at 1352, 99 U.S.P.Q.2d (BNA) at 1415. 
 66. Myriad’s Memo, supra note 5, at 31. 
 67. See Myriad, 653 F.3d at 1365, 99 U.S.P.Q.2d (BNA) at 1424 (Moore, J., 
concurring in part) (describing isolated DNA molecules as truncations); see also 
Kuehmsted v. Farbenfabriken of Elberfeld Co., 179 F. 701, 704–05 (7th Cir. 1910) 
(emphasizing the claimed aspirin’s increased therapeutic effect compared to aspirins 
purified by previous methods); Parke-Davis & Co. v. H. K. Mulford Co., 189 F. 95, 103 
(C.C.S.D.N.Y. 1911) (highlighting the therapeutic utility gained by purifying insulin 
from surrounding glandular tissue), aff’d in part, rev’d in part, 196 F. 496 (2d Cir. 
1912). 
 68. Myriad, 653 F.3d at 1365, 99 U.S.P.Q.2d (BNA) at 1425 (Moore, J., 
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do not have the chemical and structural properties needed to 
perform such functions.69  Therefore, isolated DNA molecules’ 
usefulness in diagnostic genetic testing constitutes an expansion of 
their range of utility as compared to native DNA molecules.70 
C. Maintaining Patent Eligibility of Isolated DNA Sequences Comports With 
Longstanding PTO Practice 
Since 2001, PTO policy has explicitly allowed patenting of isolated 
DNA molecules with the same sequence as naturally occurring genes, 
reasoning that DNA molecules do not exist in isolated form in 
nature.71  Prior to promulgating the current guidelines, the PTO 
began granting patents for human genes in the 1980s, issuing at least 
2600 patents claiming isolated DNA over the past twenty-nine years.72  
In the three decades that patents have been issued for isolated DNA 
molecules, Congress has refrained from intervening to exclude those 
inventions from the broad scope of § 101.73  The biotechnology 
                                                          
concurring in part); Myriad’s Memo, supra note 5, at 32; see, e.g., U.S. Patent No. 
5,693,473 (filed June 7, 1995) (disclosing the use of isolated DNA molecules 
encoding BRCA1 as probes for screening patients to determine if they carry specific 
BRCA1 mutations resulting in a predisposition for developing cancer); see also 
USPTO Utility Examination Guidelines, 66 Fed. Reg. 1092, 1094 (Jan. 5, 2001) 
(asserting that an isolated DNA molecule meets the statutory utility requirement if it 
hybridizes near and serves as a marker for a disease gene). 
 69. Myriad, 653 F.3d at 1365, 99 U.S.P.Q.2d (BNA) at 1425 (Moore, J., 
concurring in part); Myriad’s Memo, supra note 5, at 9; see also Ass’n for Molecular 
Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 181, 196, 94 
U.S.P.Q.2d (BNA) 1683, 1694–95 (S.D.N.Y. 2010) (acknowledging that isolated DNA 
can be used as a tool for biotechnological applications for which native DNA cannot 
be used), aff’d in part, rev’d in part, 653 F.3d 1329, 99 U.S.P.Q.2d 1398 (Fed. Cir. 
2011). 
 70. Myriad, 653 F.3d at 1365, 99 U.S.P.Q.2d (BNA) at 1425 (Moore, J., 
concurring in part) (quoting Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 
127, 131, 76 U.S.P.Q. (BNA) 280, 282 (1948)).  Judge Moore continued that because 
diagnostic testing “is not a natural utility,” the claimed DNA does not “serve the ends 
nature originally provided.”  Id. (quoting Funk Bros., 333 U.S. at 131, 76 U.S.P.Q. 
(BNA) at 282) (internal quotation marks omitted).  In Funk Bros., the Court, though 
acknowledging the advantage in combining six non-inhibiting strains of inoculating 
bacteria, emphasized that the combination “produce[d] no new bacteria, no change 
in the six species of bacteria, and no enlargement of the range of their utility.”  333 
U.S. at 131, 76 U.S.P.Q. (BNA) at 282.  Thus, the combination, independent of any 
effort of the patentee, “serve[d] the ends nature originally provided.”  Id., 76 
U.S.P.Q. (BNA) at 282. 
 71. See USPTO Utility Examination Guidelines, 66 Fed. Reg. at 1093 (stating that 
an inventor’s discovery of a gene can be the basis for a patent on the isolated and 
purified genetic composition as separated from other molecules with which it is 
associated in nature). 
 72. Myriad, 653 F.3d at 1355, 99 U.S.P.Q.2d (BNA) at 1418. 
 73. Id., 99 U.S.P.Q.2d (BNA) at 1418; 149 CONG. REC. 18,999 (2003) 
(acknowledging that many institutions have extensive patents on human genes but 
declining to implement legislation affecting any of those current existing patents). 
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industry’s substantial investments of time and money to secure 
property rights related to DNA sequences reflect the patent system’s 
ability to spur scientific progress.74  Consequently, the Supreme Court 
has cautioned lower courts against adopting changes with potential to 
disrupt the settled expectations of the inventing community.75  
Moreover, because the judiciary is ill-suited to determine whether 
claims to isolated DNA molecules promote or inhibit “[s]cience and 
useful [a]rts”76 in all but the clearest cases, any change should come 
from Congress.77 
CONCLUSION 
As biotechnology research intensifies, invention and discovery will 
blur the line between that which is man-made and that which is 
naturally occurring.  Where a new and useful discovery cannot be 
reproduced by nature without the aid of man, it deserves 
patentability, despite any striking similarities to a product of nature.  
The Myriad decision, emphasizing the historical framework to be 
used in § 101 analyses, underscores the need to examine the 
differences in identity between an inventive composition and a 
product of nature.78  When scrutinizing composition claims, district 
courts should take care to focus their § 101 analyses on differences in 
chemical structure, while keeping in mind that novel utility may be 
                                                          
 74. Myriad, 653 F.3d at 1368, 99 U.S.P.Q.2d (BNA) at 1427 (Moore, J., 
concurring in part); see David E. Adelman & Kathryn L. DeAngelis, Patent Metrics:  
The Mismeasure of Innovation in the Biotech Patent Debate, 85 TEX. L. REV. 1677, 1681 
(2007) (noting that empirical studies indicate that growth in the number of 
biotechnology patents issued has not impaired biotech innovation). 
 75. See Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722, 739, 
62 U.S.P.Q.2d (BNA) 1705, 1713 (2002) (advocating following precedent upon 
application of prosecution history estoppel so as to avoid destroying legitimate 
expectations of inventors in their property); Warner-Jenkinson Co. v. Hilton Davis 
Chem. Co., 520 U.S. 17, 32 n.6, 41 U.S.P.Q.2d (BNA) 1865, 1872 n.6 (1997) 
(indicating that such changes have the potential to subvert the balances the PTO 
sought to strike when issuing numerous patents that have not yet expired and would 
be affected by such a decision). 
 76. U.S. CONST. art. I, § 8, cl. 8. 
 77. Myriad, 653 F.3d at 1371, 99 U.S.P.Q.2d (BNA) at 1430 (Moore, J., 
concurring in part) (suggesting that Congress’s constitutional authority and 
institutional ability are needed to fully accommodate “‘the varied permutations of 
competing interests that are inevitably implicated by . . . new technology’” (quoting 
Sony Corp. of Am. v. Universal City Studios, Inc., 464 U.S. 417, 431, 220 U.S.P.Q. 
(BNA) 665, 674 (1984))); see, e.g., Diamond v. Chakrabarty, 447 U.S. 303, 318, 206 
U.S.P.Q. (BNA) 193, 201 (1980) (concluding that, until Congress takes action, the 
court must take the language of § 101 as it is); Gottschalk v. Benson, 409 U.S. 63, 72–
73, 175 U.S.P.Q. (BNA) 673, 676–77 (1972) (urging that a change in § 101 requires 
the broad powers of investigation that Congress progresses). 
 78. See supra Part II.A (emphasizing that § 101 analysis should be focused on a 
claimed composition’s identity compared to what exists in nature). 
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indicative of those differences.79  Accordingly, the marked differences 
in chemical structure and expanded range of utility of isolated DNA 
molecules when compared to native DNA molecules places them 
squarely within § 101 patentable subject matter.80  The Federal 
Circuit’s approach serves to promote scientific progress by leaving 
intact the settled expectations of the inventing community fostered 
by the broad language of § 101, judicial precedent, and the PTO’s 
longstanding policy and practice.81 
                                                          
 79. See id. (explaining that the Myriad majority determined that DNA chemical 
structure, rather than function, be the focus of patentability). 
 80. See supra Part II.B (describing the use of isolated genes as probes and primers 
for identification of genetic mutations as important to their utility over natural 
DNA). 
 81. See supra Part II.C (promoting only congressional alterations to patentability 
and following patentability precedent by the PTO). 
